International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN
DOI	https://doi.org/10.31435/ijitss.3(51).2026.6195
RECEIVED	19 May 2026
ACCEPTED	23 August 2026
PUBLISHED	31 August 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPAN

Katarzyna Pawłucka *(Corresponding Author, Email: kasia.pawlucka@gmail.com)*
Jagiellonian University Medical College, Krakow, Poland
ORCID ID: 0009-0001-4273-6599

Aleksandra Pawłucka
St. John Grande Hospital of the Brothers Hospitallers of Saint John of God, Kraków, Poland
ORCID ID: 0009-0005-6765-9314

Joanna Kadłuczka
Ludwik Rydygier Specialist Hospital in Cracow, Kraków, Poland
ORCID ID: 0009-0002-9347-0767

Makary Hejduk
Independent Public Health Care Facility in Myślenice, Poland
ORCID ID: 0009-0004-7579-4471

Magdalena Grzymek
The University Hospital in Krakow, Kraków, Poland
ORCID ID: 0009-0000-4337-0261

Justyna Bury
Medical University of Silesia in Katowice, Poland
ORCID ID: 0009-0001-4778-2375

Katarzyna Kraska
Medical Center in Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0004-0464-6826

Jan Potoniec
Gabriel Narutowicz Municipal Specialist Hospital in Krakow, Krakow, Poland
ORCID ID: 0009-0000-5282-7833

Weronika Kępa
Independent Researcher, Poland
ORCID ID: 0009-0000-8378-9681

Aneta Sobek
Medical Center in Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0002-6759-5419

Martyna Więcławek
The University Hospital in Krakow, Kraków, Poland
ORCID ID: 0009-0006-7956-9962

ABSTRACT

Objectives: This narrative review synthesizes current evidence regarding the modulation of psilocybin responsivity by female sex hormones (estrogen, progesterone, testosterone) across the lifespan, aiming to identify molecular mechanisms, clinical implications, and critical knowledge gaps for personalized psychedelic medicine.
Methods: Databases including PubMed, ClinicalTrials.gov, and ANZCTR were searched for literature published between 2000 and 2026. Search strategies utilized combinations of terms related to psilocybin, sex hormones, the menstrual cycle, pregnancy, menopause, and premenstrual dysphoric disorder (PMDD). Peer-reviewed studies, clinical protocols, and preclinical models were evaluated.
Main Findings: Molecular data from human PET and preclinical studies suggest that estradiol may upregulate cortical 5-HT2A receptor availability, while testosterone appears to modulate serotonin transporter (SERT) expression. These pathways potentially overlap with psilocin's pharmacodynamics. Preclinical evidence from a 2025 postpartum mouse model signals a critical warning, suggesting that postpartum psilocybin administration may paradoxically amplify anxiety-like behaviors and induce long-term anhedonia in offspring. Clinically, preliminary qualitative data suggest potential microdosing efficacy in PMDD, though rigorous randomized controlled trials are needed to confirm these findings. Major data gaps persist regarding the impact of menopause and combination oral contraceptives on psychedelic experiences.
Conclusions: Mechanistic and preclinical evidence suggests that the female hormonal landscape may influence psilocybin responsivity. However, the current lack of stratified human clinical data precludes definitive dosing or timing recommendations. Integrating hormonal tracking into future psychedelic trial designs is imperative for establishing safe, personalized therapeutic frameworks.

KEYWORDS

Psilocybin, Estrogen, Testosterone, Menstrual Cycle, Menopause, PMDD

CITATION

Katarzyna Pawłucka, Aleksandra Pawłucka, Joanna Kadłuczka, Makary Hejduk, Magdalena Grzymek, Justyna Bury, Katarzyna Kraska, Jan Potoniec, Weronika Kępa, Aneta Sobek, Martyna Więcławek. (2026). Hormonal Modulation of Psilocybin Responsivity Across the Female Reproductive Lifespan. *International Journal of Innovative Technologies in Social Science*. 3(51). doi: 10.31435/ijitss.3(51).2026.6195

1. Introduction

1.1. The Epidemiological Burden of Affective Disorders in Women

Affective disorders, primarily major depressive disorder (MDD) and various manifestations of anxiety disorders, represent some of the most pervasive and debilitating public health challenges of the twenty-first century [1,2]. According to the landmark Global Burden of Disease Study 2019, depressive disorders alone constitute a leading cause of non-fatal disease burden globally, accounting for a massive percentage of disability-adjusted life years (DALYs) across diverse demographic strata [3]. However, one of the most resilient, reproducible, and cross-culturally validated findings in psychiatric epidemiology is the profound sex-based disparity in the prevalence and severity of these conditions [4,5]. Lifelong epidemiological tracking consistently demonstrates that women are roughly twice as likely as men to experience a major depressive episode or be diagnosed with an anxiety disorder during their lifetime [4,5].

This pronounced clinical divergence between the sexes does not exist throughout the entire human lifespan; rather, it exhibits a distinct temporality that implicates endocrine architecture. During early childhood and pre-pubertal development, the rates of depressive and anxious symptomatology are virtually identical between boys and girls [6]. The female-to-male prevalence ratio of approximately 2:1 emerges precipitously during the onset of puberty, a developmental milestone characterized by the activation of the hypothalamic-pituitary-gonadal (HPG) axis and the subsequent cyclical surge of ovarian steroids, namely 17β-estradiol and progesterone [2,6,11]. This elevated vulnerability remains highly pronounced throughout the female reproductive years and is uniquely exacerbated during windows of profound, rapid neuroendocrine transitions [2,11]. Such transition phases—including the luteal phase of the menstrual cycle, the peripartum period, and the perimenopausal transition—are neurobiologically characterized by volatile fluctuations or precipitous withdrawals of gonadal steroids, which fundamentally destabilize emotional processing and mood regulation networks in vulnerable individuals [2,11,23].

1.2. The Neurobiology of the "Telescoping Effect" and Substance Use in Females

The sex-specific disparities in psychiatric pathology extend far beyond primary mood disorders into the domain of substance use disorders (SUDs), where women present with highly distinct clinical trajectories and escalation patterns [7,8]. Historically, addiction research was overwhelmingly biased toward male subjects, under the false assumption that lower baseline prevalence rates of substance abuse in women rendered their neurobiology secondary [2,7]. Contemporary clinical and preclinical evidence has thoroughly dismantled this bias, highlighting a phenomenon known as the "telescoping effect" [7]. The telescoping effect describes a highly accelerated clinical course observed in women, wherein the duration between the initial, recreational introduction to a psychoactive substance (such as alcohol, cannabinoids, stimulants, or opioids) and the development of physiological dependence, compulsive seeking, and treatment-seeking behavior is significantly compressed compared to men [7].

Neurobiologically, the telescoping effect is tightly coupled with the neuromodulatory actions of ovarian hormones, particularly estradiol [22]. Preclinical models suggest that estradiol may enhance the rewarding efficacy of drugs of abuse by directly modulating the mesolimbic dopamine pathway [9,22]. Estradiol appears to accelerate the rate of behavioral sensitization and potentiate drug-induced dopamine release within the nucleus accumbens [8,9]. Conversely, progesterone and its neuroactive steroid metabolites, such as allopregnanolone, may act as natural buffers, attenuating stress-induced reinstatement and reducing drug-craving behavior during specific phases [2]. Furthermore, women may face higher relapse rates during periods of hormonal withdrawal, an effect potentially driven by the intersection of stress-responsivity networks, the hypothalamic-pituitary-adrenal (HPA) axis, and cyclical gonadal fluctuations [7,8]. Understanding these accelerated trajectories is critical as the medical community seeks to implement novel interventions for addiction, such as psychedelic-assisted therapy, which must be tailored to navigate these highly dynamic female-specific vulnerabilities.

1.3. Psilocybin: Historical Context, Contemporary Renaissance, and Mechanisms

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), a naturally occurring tryptamine alkaloid synthesized by over 180 species of Psilocybe mushrooms, is currently at the vanguard of a profound paradigm shift in psychiatric medicine [10]. The history of psilocybin is characterized by a dramatic trajectory: spanning centuries of indigenous ritualistic and sacramental utilization, transitioning into a burst of intense clinical and psychotherapeutic exploration during the mid-twentieth century, followed by a multi-decadal period of complete scientific stagnation enforced by political prohibition via the United States Controlled Substances Act of 1970 [10,11]. In the current contemporary "psychedelic renaissance," psilocybin has re-emerged as a highly promising, disruptive transdiagnostic therapeutic agent [11]. Rigorous randomized, double-blind, placebo-controlled clinical trials have provided compelling, high-grade evidence demonstrating that psilocybin administration, when combined with structured psychological support, may induce rapid, profound, and exceptionally long-lasting therapeutic remissions in patients suffering from MDD, treatment-resistant depression (TRD), existential anxiety secondary to life-threatening cancer diagnoses, post-traumatic stress disorder (PTSD), and treatment-resistant alcohol and tobacco use disorders [11,12,13,14]. A recent pooled safety analysis of 85 healthy volunteers confirmed that acute psilocybin administration is well-tolerated, with no serious adverse events reported across doses ranging from 15 to 30 mg [37].

The unique clinical profile of psilocybin lies in its ability to achieve sustained therapeutic outcomes following only one or two acute, high-dose administrations, contrasting sharply with the daily, chronic dosing regimens required by conventional monoaminergic antidepressants [12,14]. Mechanistically, psilocybin functions strictly as a prodrug [10]. Upon oral ingestion, it undergoes rapid and extensive first-pass metabolism via ubiquitous alkaline phosphatases, which dephosphorylate the molecule into its active, lipophilic, and blood-brain barrier-permeable metabolite, psilocin (4-hydroxy-N,N-dimethyltryptamine) [10]. Psilocin exhibits structural homology with the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) and operates primarily as a high-affinity partial-to-full agonist at the serotonin 2A (5-HT2A) receptor subtype, with additional minor affinities at 5-HT1A, 5-HT1B, and 5-HT2C receptors [10,15,34].

At the cellular level, the binding of psilocin to the 5-HT2A receptor—which is a G-protein-coupled receptor predominantly localized on the apical dendrites of glutamatergic pyramidal neurons in cortical layer V—triggers a complex intracellular signaling cascade [17,18]. This activation stimulates phospholipase C (PLC), resulting in the downstream hydrolysis of phosphoinositides to generate inositol triphosphate (IP3) and diacylglycerol (DAG) [18]. This cascade induces a massive intracellular release of calcium ions (Ca^{2+}), which activates protein kinase C (PKC) and subsequently drives the intracellular transcription of immediate early

genes and neurotrophic factors, most notably brain-derived neurotrophic factor (BDNF) [16,18]. Concurrently, psilocin-induced 5-HT2A activation stimulates the mammalian target of rapamycin (mTOR) signaling pathway [16]. Together, the surge in BDNF expression and mTOR activation promotes profound, rapid structural and functional neuroplasticity, characterized by the rapid remodeling of dendritic spines, enhanced synaptogenesis, and the restoration of lost synaptic connectivity in frontocortical and hippocampal circuits that have been severely atrophied by chronic stress or depression [16,19,20].

At the macroscopic, systems-level architecture of the brain, neuroimaging studies utilizing functional magnetic resonance imaging (fMRI) demonstrate that acute psilocin administration causes a profound, immediate desynchronization of high-level cortical networks [19,21]. Specifically, psilocin suppresses the functional connectivity and integrity of the Default Mode Network (DMN), a highly interconnected network encompassing the medial prefrontal cortex, posterior cingulate cortex, and precuneus [19]. The DMN is known to mediate self-referential processing, autobiographical memory, and the construct of the narrative "ego" or "self" [19]. In states of severe depression and anxiety, the DMN is characteristically hyper-connected and rigid, manifesting clinically as pathological, repetitive, negative rumination [19]. By transiently dismantling the rigid boundaries of the DMN, psilocin induces an increase in global brain entropy and functional connectivity, allowing brain regions that do not typically interact to communicate fluidly [21,22]. This "rebus" or "network reset" model may provide patients with a highly valuable window of cognitive flexibility, enabling them to escape deeply ingrained maladaptive cognitive ruts and reframe their emotional traumas [21,22].

1.4. The Critical Gap: Historical Neglect of Female Physiology in Psychedelic Trials

Despite the undeniable momentum of psychedelic medicine and its imminent integration into mainstream psychiatry, a glaring, historically continuous methodological blind spot remains: the systemic neglect of female-specific physiology and neuroendocrinology [2]. As Cohen and Blest-Hopley critically highlighted, the overwhelming majority of contemporary, high-impact clinical trials exploring psilocybin for MDD, TRD, and SUDs have treated biological sex as a mere demographic covariate to be statistically controlled, rather than a fundamental biological variable of primary interest [2]. Even more concerningly, these trial protocols almost universally fail to track, record, or stratify their clinical data based on essential parameters of female reproductive biology [2,11]. These parameters include the specific phase of the menstrual cycle at the time of psilocybin dosing, the concurrent use of various classes of hormonal contraceptives, perimenopausal status, or history of premenstrual dysphoric disorders [2].

This complete omission represents a severe scientific vulnerability, because the central serotonergic system—the absolute primary pharmacodynamic target of psilocybin and psilocin—is not a static neurobiological background [13,22]. Rather, the serotonergic system is profoundly modulated, remodeled, and behaviorally fine-tuned by fluctuating concentrations of circulating sex hormones across the entire female lifespan [13,22]. Estrogen, progesterone, and testosterone are potent neuroactive steroids capable of crossing the blood-brain barrier to bind to their respective nuclear and membrane-bound receptors, which are densely co-localized with 5-HT2A receptors within key emotional-processing hubs: the prefrontal cortex, the hippocampus, and the amygdala complex [17,22]. These hormones fundamentally alter serotonin synthesis rates, change the density and binding affinity of 5-HT2A receptors, and modulate the clearance kinetics of the serotonin transporter (SERT) [22].

Fields of clinical research must acknowledge that giving an identical weight-adjusted or fixed dose of psilocybin to a woman in a high-estrogen state (e.g., the late follicular or ovulatory phase) versus a low-estrogen state (e.g., the early follicular or late luteal phase), or to a woman whose endogenous cycle is completely suppressed by synthetic steroids via oral contraceptives, may theoretically produce highly variable pharmacokinetic, pharmacodynamic, and subjective clinical outcomes [2,13]. Indeed, neuroimaging evidence reviewed by Sacher et al. confirms robust sexual dimorphism in human brain structure and function, underscoring that the neural substrates targeted by psilocybin are not sexually neutral [32]. Testing these substances predominantly in male animals and human cohorts, and extrapolating those findings directly to the female population, is a significant limitation that could compromise both patient safety and therapeutic efficacy.

1.5. Review Aim and Structured Research Questions

To address this critical gap, this narrative review synthesizes the available molecular, preclinical, and emerging clinical evidence surrounding the direct and indirect interactions between female sex hormones and the psilocybin mechanism of action across the female lifespan [13]. This synthesis aims to construct a coherent conceptual framework that moves the field of psychedelic science away from a rigid, "one-size-fits-all" dosing model and toward an endocrinologically informed, personalized approach to psychedelic-assisted psychopharmacology [2,13].

To maintain strict scientific transparency and analytical rigor, our narrative analysis was guided by four explicit, pre-defined research questions:

1. What specific molecular, cellular, and neuroimaging mechanisms link circulating levels of estrogen and testosterone to the baseline expression, availability, and functional signaling of the central serotonergic system, particularly the 5-HT2A receptor and the serotonin transporter (SERT)?

2. Does the predictable fluctuation of gonadal hormones across the natural human menstrual cycle influence the intensity, quality, or therapeutic efficacy of acute psilocybin administration?

3. What empirical evidence, registered clinical trial protocols, or preclinical data exist regarding the safety, tolerability, and clinical efficacy of psilocybin or related classic psychedelics within specific female reproductive and clinical context windows, namely Premenstrual Dysphoric Disorder (PMDD), pregnancy, the postpartum lactation period, and the perimenopausal/postmenopausal transition?

4. What are the primary methodological gaps, blind spots, and concrete future research directions required to fully establish an evidence-based, personalized, and hormone-stratified framework for psychedelic therapy in women?

2. Methodology

2.1. Systematic Search Strategy and Information Sources

To ensure comprehensive coverage of the literature while maintaining the integrative flexibility of a narrative review, a literature search was executed across three primary databases: PubMed/MEDLINE, ClinicalTrials.gov (the U.S. National Institutes of Health registry), and the Australian New Zealand Clinical Trials Registry (ANZCTR). The search window was restricted from January 1, 2000, to March 31, 2026, to capture the modern era of the psychedelic renaissance and the most up-to-date clinical trial protocols. However, landmark historical papers or fundamental neuroendocrinology studies published prior to 2000 (e.g., Sumner and Fink, 1995) were manually integrated if they provided foundational mechanistic data regarding steroid-serotonin interactions that have not been superseded by modern research [25].

The literature search was formally completed in March 2026. To ensure maximal sensitivity, database-specific search strings were constructed using combinations of Medical Subject Headings (MeSH) terms, keywords, and Boolean operators (AND, OR). A representative, highly sensitive search string applied to the PubMed database was structured as follows:

(("psilocybin"[MeSH Terms] OR "psilocybin"[All Fields] OR "psilocin"[All Fields] OR "psychedelics"[MeSH Terms] OR "psychedelics"[All Fields] OR "classic psychedelic"[All Fields]) AND ("estrogens"[MeSH Terms] OR "estrogens"[All Fields] OR "estrogen"[All Fields] OR "estradiol"[All Fields] OR "progesterone"[MeSH Terms] OR "progesterone"[All Fields] OR "testosterone"[MeSH Terms] OR "testosterone"[All Fields] OR "gonadal steroid"[All Fields] OR "sex hormones"[MeSH Terms] OR "sex hormones"[All Fields])) AND ("menstrual cycle"[MeSH Terms] OR "menstrual cycle"[All Fields] OR "follicular phase"[All Fields] OR "luteal phase"[All Fields] OR "pregnancy"[MeSH Terms] OR "pregnancy"[All Fields] OR "postpartum period"[MeSH Terms] OR "postpartum"[All Fields] OR "lactation"[MeSH Terms] OR "lactation"[All Fields] OR "menopause"[MeSH Terms] OR "menopause"[All Fields] OR "perimenopause"[All Fields] OR "contraceptives, oral, hormonal"[MeSH Terms] OR "oral contraceptives"[All Fields] OR "premenstrual dysphoric disorder"[MeSH Terms] OR "PMDD"[All Fields])

In addition to formal database queries, secondary search strategies included a meticulous manual screening of the reference bibliographies of all selected primary articles, high-impact systematic reviews, and meta-analyses to identify any relevant grey literature, thesis documents, or deeply embedded landmark publications that might have escaped the automated electronic search.

2.2. Explicit Inclusion and Exclusion Criteria

To guide the selection process and ensure the high quality of the synthesized data, strict inclusion and exclusion criteria were established a priori.

Inclusion Criteria:

- Peer-reviewed, original human clinical trials (Open-label, Phase 1, Phase 2, or Phase 3 RCTs) evaluating classic psychedelics.
- Preclinical animal model studies (in vivo or in vitro) investigating the administration of psilocybin, psilocin, or direct 5-HT2A agonists where the biological sex of the animals was explicitly tracked, or where gonadal status (e.g., ovariectomy, estrous cycle tracking, hormone replacement) was manipulated.
- Official, active, or completed clinical trial protocols registered on international repositories (ClinicalTrials.gov, ANZCTR) mapping out novel psychedelic interventions for female-specific indications.
- Human neuroimaging studies (PET, SPECT, fMRI) evaluating the direct impact of exogenous or endogenous sex steroids on serotonin receptor architecture or network connectivity.
- Articles published in the English language.

Exclusion Criteria:

- Studies evaluating exclusively non-classic or atypical psychedelic agents (e.g., ketamine, esketamine, MDMA, ibogaine) unless they were explicitly utilized within a comparative pharmacodynamic framework to illustrate unique 5-HT2A monoaminergic interactions.
- Editorials, general opinion pieces, high-level non-peer-reviewed popular media articles, or conference abstracts that lacked accessible, full-text methodology and data sets.
- Studies focusing exclusively on male human cohorts or male animal models without any comparative female tracking or neuroendocrine cross-referencing.

2.3. Hierarchical Classification of Evidence Levels

To provide readers, clinicians, and researchers with a clear indication of data reliability, all extracted findings and primary sources were critically evaluated and assigned an explicit Hierarchical Evidence Level. This multi-tiered classification framework was adapted from the standardized guidelines established by the Oxford Centre for Evidence-Based Medicine (OCEBM) and was tailored to the unique landscape of contemporary psychedelic research:

Level A – High-Grade Evidence: Peer-reviewed human clinical trials (randomized, double-blind, placebo-controlled), prospective cohort studies, or human neuroimaging investigations utilizing gold-standard techniques (e.g., Positron Emission Tomography [PET] with validated radioligands like [11C]Cimbi-36 or [18F]altanserin) evaluating human clinical populations [15,30].

Level B – Moderate-Grade Evidence: Methodologically rigorous, peer-reviewed preclinical animal models (in vivo behavioral assays, microdialysis, immunohistochemistry, or Western blot analyses in rodents or non-human primates) evaluating explicit mechanistic interactions between hormones and psychedelics [27,33].

Level C – Low-Grade/Emerging Clinical Evidence: Official clinical trial protocols registered on ClinicalTrials.gov or ANZCTR that are currently active, recruiting, or completed but lack peer-reviewed, published final data sets; also includes indirect human physiological or stress-reactivity data extrapolated from general psychiatric literature [22,27].

Level D – Preliminary/Exploratory Evidence: Unpublished academic theses, retrospective qualitative self-report survey data, crowd-sourced microdosing data, case reports, or theoretical mechanistic hypotheses that have not yet undergone direct clinical validation in human populations [2,13].

2.4. Data Extraction, Synthesis Process, and Methodological Limitations

The data extraction process was conducted in a standardized, independent, two-stage sequence. First, two investigators independently screened the titles and abstracts of all 412 unique records generated by the initial automated search string to eliminate irrelevant or highly tangential papers. Second, the remaining full-text articles were evaluated against the strict inclusion and exclusion criteria. Disagreements regarding inclusion were resolved through mutual consultation and consensus. Ultimately, 37 unique, highly relevant publications were selected for final integration into the narrative synthesis. For each included source, a standardized data extraction matrix was populated, capturing: primary author, year of publication, specific study design, biological model/target population, precise endocrine/hormonal variable measured, explicit psilocybin/psychedelic variable measured, primary outcomes, and identified methodological limitations.

This methodology possesses inherent limitations that must be transparently noted. As a narrative, qualitative review rather than a formal, quantitative systematic review or meta-analysis, this work does not utilize a rigid, mathematical pooling of effect sizes (such as Cohen's d or Hedges' g), nor does it apply a formal, automated risk-of-bias assessment tool (such as the Cochrane Risk of Bias tool). The descriptive and comparative analysis presented herein relies on the critical qualitative synthesis of highly heterogeneous data sets, ranging from cellular animal assays to human neuroimaging and qualitative patient interviews. Consequently, potential selection bias cannot be completely excluded. This limitation is addressed in detail within the Discussion section.

3. Results

3.1. Molecular and Neuroimaging Mechanisms: Estrogen, Testosterone, and 5-HT2A / SERT Architecture

The interaction between biological sex steroids and the central serotonergic system represents a foundational pillar of modern neuroendocrinology. The primary pharmacodynamic target of psilocybin's active metabolite, psilocin, is the serotonin 2A (5-HT2A) receptor [10,34]. Evidence suggests that the density, distribution, and binding affinity of this specific receptor may be modulated by circulating levels of 17β-estradiol [15,22]. In a landmark human neuroimaging study utilizing Positron Emission Tomography (PET) with the validated radioligand [18F]altanserin, Kugaya and colleagues demonstrated that cortical 5-HT2A receptor binding availability is significantly higher in postmenopausal women receiving estrogen replacement therapy compared to those not receiving treatment [Evidence Level A][15].

Mechanistically, this may be driven by the fact that estrogen acts as a potent transcriptional regulator [22]. Intracellularly, 17β-estradiol binds to nuclear estrogen receptors alpha (ERα) and beta (ERβ), which subsequently translocate to the nucleus and bind directly to estrogen response elements (EREs) located within the promoter region of the HTR2A gene (the gene encoding the 5-HT2A receptor) [Evidence Level B] [22,26,28]. This genomic mechanism may trigger a robust upregulation of 5-HT2A receptor mRNA expression and subsequent protein synthesis in key emotional-processing and cognitive hubs, including the medial prefrontal cortex (mPFC), the anterior cingulate cortex (ACC), and the hippocampus [22,28].

Furthermore, estradiol may act via membrane-bound G-protein coupled estrogen receptors (GPER) to initiate rapid, non-genomic signaling cascades [22]. These cascades may activate intracellular mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, which directly phosphorylate and sensitize existing 5-HT2A receptors, enhancing their coupling efficiency to downstream G-proteins [18,22,29]. Consequently, during physiological windows characterized by peak estradiol concentrations, such as the late follicular and ovulatory phases of the natural menstrual cycle, the frontocortical networks may be neurobiologically "primed" for enhanced responsiveness to 5-HT2A receptor agonists, theoretically amplifying both the subjective and neuroplastic effects of an identical dose of psilocybin [2,13]. These molecular interactions are summarized in Table 1.

Table 1. Summary of Steroid Hormone Effects on Serotonergic Targets

Steroid Hormone	Primary Molecular Target	Major Neuroanatomical Loci	Impact on Target	Potential Consequence for Psilocybin Therapy
17β-Estradiol	HTR2A Gene /5HT2AReceptor	mPFC, ACC, Hippocampus	Upregulates mRNA and protein synthesis; sensitizes G-protein coupling	May amplify psychedelic intensity and neuroplastic capacity
Progesterone	MAO-A /GABA A Receptors	Amygdala, Hypothalamus	Enhances MAO-A degradation of monoamines; promotes allopregnanolone sedation	May blunt the acute psychedelic experience
Testosterone	SLC6A4 Gene / SERT	Dorsal Raphe Nuclei, Striatum	Upregulates SERT expression; accelerates serotonin clearance	May alter baseline serotonin tone; could elevate the necessary threshold dose

Conversely, testosterone exerts a distinct, highly regulatory influence on the serotonin transporter (SERT), the protein responsible for the reuptake of serotonin from the synaptic cleft back into the presynaptic terminal [21]. In a profound human PET imaging paradigm evaluating individuals undergoing cross-sex hormone therapy for gender dysphoria, Kranz et al. demonstrated that long-term administration of high-dose exogenous testosterone induces a statistically significant, widespread increase in SERT binding availability throughout the human brain, particularly within the dorsal raphe nuclei and the striatum [Evidence Level A] [21].

At the molecular level, testosterone may bind to androgen receptors (AR) which interact with the promoter regions of the SLC6A4 gene (encoding SERT), driving enhanced gene transcription [Evidence Level B] [21]. By upregulating SERT, testosterone may drastically accelerate the clearance kinetics of synaptic serotonin, thereby lowering baseline endogenous serotonergic tone within frontostriatal circuits [21]. Because endogenous serotonin competes directly with exogenous psilocin for binding at the 5-HT2A receptor site, a higher baseline density of SERT (and a resulting lower synaptic serotonin concentration) leaves a greater percentage of 5-HT2A receptors unoccupied and highly vulnerable to psilocin binding [10,21]. This interaction suggests that the androgenic profile of an individual represents an important biochemical variable that dictates baseline receptor occupancy thresholds, a finding that may have profound implications for optimizing dosing protocols in clinical settings [2,13].

3.2. Menstrual Cycle Fluctuations: Potential Cyclical Variations in Psychedelic Responsivity

The human menstrual cycle is a highly dynamic 28-day endocrine cycle characterized by predictable, sweeping fluctuations in ovarian steroids, which induce significant structural and functional remodeling of the female brain [6,24]. In a rigorous, long-term prospective longitudinal study tracking healthy, naturally cycling women over multiple months, Taylor et al. utilized high-field structural MRI and functional connectivity analysis to demonstrate that the human brain exhibits remarkable structural elasticity across the cycle [Evidence Level A] [24]. Specifically, during the late follicular phase—when 17β-estradiol reaches its biological peak and progesterone remains at baseline low levels—women display a significant increase in grey matter volume and enhanced functional connectivity within the hippocampus and the parahippocampal gyrus, areas absolutely central to memory consolidation and emotional regulation [24]. Concurrently, fMRI resting-state data show that high-estrogen states are characterized by increased functional connectivity between the mPFC and the executive control network, rendering the brain more structurally organized yet paradoxically more responsive to external and internal emotional shifts [24].

During the subsequent luteal phase, the endocrine landscape shifts dramatically: estradiol drops into a secondary, lower plateau, while progesterone surges to its peak [6]. Progesterone is rapidly metabolized in the central nervous system into allopregnanolone, a potent, positive allosteric modulator of GABAA receptors [2,6]. High concentrations of allopregnanolone induce an influx of chloride ions (Cl-) into post-synaptic neurons, causing widespread hyperpolarization and a generalized dampening of neuronal excitability, particularly within the amygdala complex [2]. Furthermore, progesterone may upregulate the expression and activity of monoamine oxidase A (MAO-A), the primary enzyme responsible for the metabolic degradation of intracellular monoamines, including serotonin and psilocin [Evidence Level B] [22].

This cyclical divergence generates a compelling neurobiological hypothesis regarding psilocybin responsivity [2,13]. In the high-estrogen/low-progesterone late follicular phase, the combination of upregulated 5-HT2A receptors, enhanced hippocampal connectivity, and low MAO-A activity may create a physiological landscape for an optimal, highly profound psilocybin experience, potentially maximizing the therapeutic "window of opportunity" for synaptogenesis [13,16,22]. Conversely, during the late luteal phase, elevated progesterone and allopregnanolone levels may act as a natural pharmacological "brake" or "buffer," potentially blunting the psychedelic experience, altering the threshold required to achieve ego-dissolution, and increasing the metabolic clearance rate of psilocin via elevated MAO-A pathways [2,22]. Despite the profound clinical implications of these mechanisms, contemporary human psychedelic trials continue to ignore menstrual cycle phase tracking during active dosing sessions [2].

3.3. Specific Context Windows Across the Female Lifespan

Premenstrual Dysphoric Disorder (PMDD) and Microdosing

Premenstrual Dysphoric Disorder (PMDD) is a severe, debilitating neuroendocrine condition affecting approximately 3–8% of women of reproductive age [23,31]. It is characterized by severe, cyclical, and unremitting affective symptoms—including profound depression, suicidal ideation, extreme irritability, and severe anxiety—that manifest exclusively during the luteal phase of the menstrual cycle and remit rapidly within days of the onset of menses [23,31]. Critically, women with PMDD do not exhibit abnormal baseline concentrations of circulating peripheral sex hormones; rather, their condition may be driven by a profound, genetically determined neurobiological hypersensitivity to normal, physiological fluctuations in allopregnanolone and progesterone within the brain [23,35]. This hypersensitivity may cause a paradoxical destabilization of GABAA receptor subunit configuration and a concurrent drop in central serotonergic tone during the luteal phase, leading to acute emotional dysregulation [23,36].

In recent years, the practice of psychedelic "microdosing"—the repeated ingestion of sub-hallucinogenic doses of psilocybin (typically 0.1–0.3 mg of dried mushroom equivalent, or roughly 1–3 mg of pure psilocybin compound)—has grown in popularity among women seeking alternative treatments for PMDD [2,13]. Preliminary qualitative data from self-report surveys suggest that some women report reductions in luteal-phase irritability, cyclic depression, and emotional volatility when using microdosing protocols [2,13]. However, these findings are based on uncontrolled, retrospective self-reports and must be interpreted with caution [Evidence Level D].

To transition these exploratory findings into the domain of high-grade, rigorous clinical science, future randomized, double-blind, placebo-controlled clinical trials are urgently needed. Such trials would represent a major milestone in female-centered psychedelic research, explicitly designed to determine whether low-dose psilocybin can stabilize the downstream serotonergic networks that may become destabilized by luteal-phase allopregnanolone fluctuations, potentially offering a targeted treatment paradigm for a historically underserved clinical population [2,23].

Pregnancy and Postpartum: A Critical Research Gap

While the data surrounding PMDD offer therapeutic promise, a critical and profound scientific gap exists regarding the safety of psilocybin administration during the highly sensitive postpartum period. In a groundbreaking and methodologically rigorous preclinical study published in early 2025, Hatzipantelis et al. explored the neurological and behavioral impacts of postpartum psilocybin administration using a validated mouse model [Evidence Level B] [33]. The researchers sought to investigate whether psilocybin could serve as a rapid-acting intervention for postpartum depression, a condition that affects millions of human mothers worldwide [33]. However, their empirical findings revealed a stark, unexpected, and deeply concerning paradox [33].

The investigators administered standard, pharmacologically active doses of psilocybin to female mice during early lactation (postpartum days 4–7), a period characterized by a dramatic, precipitous withdrawal of gestational hormones (progesterone and estrogen) and a concomitant surge in the lactogenic hormones prolactin and oxytocin [33]. Following administration, the maternal mice were subjected to a battery of highly validated behavioral assays, including the Elevated Plus Maze (EPM), the Open Field Test (OFT), and the Forced Swim Test (FST) [33].

Astonishingly, rather than inducing the rapid anxiolytic and antidepressant-like remissions typically observed in standard male rodent models, psilocybin administration in postpartum dams paradoxically amplified anxiety-like behaviors to an extreme degree [33]. In the EPM, treated dams spent significantly less time exploring the open arms, and in the OFT, they exhibited profound thigmotaxis (hugging the outer walls), signaling a highly elevated state of generalized fear and hyper-arousal [33].

To uncover the underlying molecular pathology of this paradoxical response, Hatzipantelis et al. performed high-resolution immunohistochemistry and Western blot analyses on the brains of the treated dams [33]. They discovered that the immediate postpartum period is characterized by a temporary, localized downregulation of 5-HT2A receptor density in the maternal medial prefrontal cortex, combined with a profound hyper-reactivity of the hypothalamic-pituitary-adrenal (HPA) axis triggered by the sudden loss of protective gestational steroids [33]. When psilocin bound to the remaining 5-HT2A receptors within this biochemically vulnerable landscape, it over-stimulated the hyper-reactive HPA axis, driving a massive, uncontrolled surge in corticosterone (the primary rodent stress hormone) and inducing a state of acute neuroinflammatory and behavioral distress rather than therapeutic relief [33].

Even more concerningly, the study tracked the long-term neurodevelopmental outcomes of the offspring that were raised by the dams treated with postpartum psilocybin [33]. Although direct cross-placental exposure was avoided by treating the dams post-birth, the researchers discovered that the acute behavioral distress and altered maternal care behavior of the mothers, combined with the excretion of trace psilocybin metabolites via breastmilk, induced profound, long-lasting behavioral alterations in the offspring as they reached adulthood [33].

The adult offspring exhibited severe long-term anhedonia, quantified by a profound lack of interest in high-reward stimuli during the Sucrose Preference Test (SPT) [33]. Mechanistic evaluation of the offsprings' brains revealed a significant disruption in structural neuroplasticity, characterized by an aberrant, disorganized pattern of synaptogenesis and dendritic pruning within the nucleus accumbens and the ventral tegmental area (VTA)—the core components of the mammalian reward pathway [33]. This critical preclinical study serves as a stark warning to the scientific and medical community: the neuroendocrine environment of the postpartum period is fundamentally unique, and extrapolating safety data from non-postpartum human cohorts or male animal models is a dangerous methodological flaw that could result in severe adverse outcomes for both mother and child [2,33].

Menopause and the Ovarian Hormone Decline

The perimenopausal and postmenopausal transitions represent the final major neuroendocrine milestones in the female lifespan, characterized by the progressive, permanent depletion of the ovarian follicular reserve and a subsequent, permanent drop in circulating levels of 17β-estradiol and progesterone [6,22]. This systemic loss of sex steroids may induce a profound, permanent downregulation of cortical 5-HT2A receptor availability, accompanied by a significant decline in baseline BDNF expression and a progressive loss of structural synaptic density within frontocortical and limbic networks [16,22]. Clinically, this phase is characterized by a sharp spike in the incidence of new-onset or recurrent major depressive episodes, severe sleep fragmentation, and progressive cognitive decline, frequently referred to as "menopausal brain fog" [11,22].

In theory, the postmenopausal brain may represent an ideal target for psilocybin-assisted therapy [11,13]. By directly binding to the remaining 5-HT2A receptors, psilocin could act as a powerful catalyst to jump-start the dormant mTOR and BDNF pathways, stimulating rapid synaptogenesis and restoring the structural plasticity that was lost due to the absence of trophic support from endogenous estrogen [16,20]. This mechanism could offer postmenopausal women a rapid, highly effective alternative to traditional hormone replacement therapy (HRT) or conventional SSRIs for managing affective decline [11,13].

However, a critical data gap persists: there is an absolute, complete absence of human clinical trials exploring psilocybin that have explicitly stratified or evaluated postmenopausal human cohorts [Evidence Level C] [2]. Current literature contains zero data regarding how the permanent absence of circulating estrogen alters the subjective quality of a high-dose psilocybin experience, whether it increases the risk of challenging psychological integrations, or whether it alters the longevity of the therapeutic effect [2]. This complete lack of empirical evidence leaves clinicians entirely in the dark regarding how to optimize safety or dosing for menopausal women [2].

3.4. Summary of Main Findings

However, a critical data gap persists: there is an absolute, complete absence of human clinical trials exploring psilocybin that have explicitly stratified or evaluated postmenopausal human cohorts [Evidence Level C] [2]. Current literature contains zero data regarding how the permanent absence of circulating estrogen alters the subjective quality of a high-dose psilocybin experience, whether it increases the risk of challenging psychological integrations, or whether it alters the longevity of the therapeutic effect [2]. This complete lack of empirical evidence leaves clinicians entirely in the dark regarding how to optimize safety or dosing for menopausal women [2].

The synthesized evidence reveals a strong mechanistic foundation for hormone-psychedelic interactions at the molecular and preclinical levels, yet a profound absence of stratified human clinical data persists across all reproductive life stages **[15,21,22,33]**. The major evidence gaps identified across all levels of evidence are summarized in Table 2.

Table 2. Summary of evidence on hormonal modulation of psilocybin response in women.

Evidence Level	Domain / Hormonal Target	Key Mechanistic Finding	Identified Major Clinical Gap
Level A (Human PET/fMRI)	Estrogen->HT2A Testosterone ->SERT Menstrual Cycle	Estradiol increases cortical 5-HT2A density/binding [15,25]. Testosterone upregulates SERT, accelerating clearance [21]. High-estrogen phases show enhanced connectivity [24].	No direct clinical testing of psilocybin in stratified hormonal states. Androgenic threshold dosing models remain completely unexplored. Lack of tracking cycle phases during psychedelic clinical trials.
Level B (Preclinical)	Genomic Mechanisms Pregnancy & Postpartum	Estradiol acts as transcriptional regulator for HTR2A gene [22,26,28]. Postpartum psilocybin in mice amplifies anxiety/anhedonia [33].	Potential translational barriers between rodents and human physiology. Total lack of human safety data regarding lactation/postpartum use.
Level C (Indirect)	Phase-Dependent Tripping	Hypothesized variations in acute trip intensity based on cycle.	No registered or active clinical trials exploring phase-specific dosing.
Level D (Qualitative)	PMDD Hormonal Contraceptives Menopause	Preliminary qualitative data signal microdosing efficacy [2,13]. Synthetic steroids flatten natural hormonal peaks [2,13]. Hypothesized altered responsivity due to estrogen decline [2].	Total absence of rigorous, placebo-controlled randomized trials. No direct studies evaluating oral contraceptive modulation. Complete demographic and clinical blind spot in medical literature.

4. Discussion

4.1. Integration of Mechanisms: The Endocrine-Psychedelic Interplay

The synthesis of the molecular, preclinical, and emerging clinical evidence compiled in this review suggests that the central serotonergic system—the primary target of classic psychedelics—is intrinsically linked to the female endocrine architecture [15,21,22]. The current dominant model of psychedelic therapy operates under a rigid, sex-neutral paradigm, assuming that a standardized, weight-adjusted or fixed dose of psilocybin will produce uniform pharmacodynamic effects regardless of the patient's hormonal status [2,13]. The data presented here suggest that this assumption may be flawed, indicating that circulating levels of estrogen, progesterone, and testosterone may actively remodel the very receptors, transporters, and intracellular signaling cascades that psilocin relies upon to induce its therapeutic effects [15,21,22].

A woman undergoing a psilocybin session during a peak estradiol window (such as the late follicular phase) may be operating within a highly sensitized neural landscape [15,24]. The elevated density of cortical 5-HT2A receptors and enhanced functional connectivity of the hippocampus may lower the threshold required to achieve profound, therapeutic ego-dissolution, while simultaneously maximizing the subsequent downstream surge in BDNF and synaptogenesis [15,16,24]. Conversely, administering the exact same dose during a low-estrogen, high-progesterone phase or to a patient taking oral contraceptives may result in relative receptor under-stimulation, blunted subjective experiences, and diminished long-term clinical efficacy due to the competing, suppressive actions of allopregnanolone and elevated MAO-A degradation pathways [2,22]. Clinicians must begin to recognize that the female hormonal landscape is not a collection of confounding variables to be ignored, but rather a powerful, dynamic modulator that may shape the biological setting of the psychedelic experience [2,13].

4.2. Methodological "Blind Spots" and Clinical Trial Flaws

The systematic omission of endocrine tracking in contemporary psychedelic trials represents a significant methodological vulnerability that compromises the scientific integrity and reproducibility of the field [2]. By failing to record the menstrual cycle phase, the type and dose of concurrent hormonal contraceptives, or the precise menopausal status of female participants, current high-impact trials may be introducing massive, uncontrolled biochemical variance into their data sets [2]. For example, if a clinical trial for TRD includes a female cohort where half the participants are in their late follicular phase and the other half are taking combination oral contraceptives (which suppress endogenous estradiol and flatten receptor availability), the resulting data will display highly erratic variance [2,15]. This variance is then erroneously

attributed to psychological factors or idiosyncratic drug responsiveness, when it may actually be driven by predictable, underlying neuroendocrine differences [2].

Furthermore, this systemic blind spot introduces significant, unquantified safety risks, as highlighted by the alarming findings of the Hatzipantelis et al. (2025) postpartum mouse model [33]. The discovery that psilocybin administration during a window of acute hormonal withdrawal can paradoxically exacerbate anxiety and induce long-term reward system deficits in offspring underscores the danger of assuming uniform safety profiles across all physiological states [33]. If human clinical trials continue to expand without explicitly excluding or closely monitoring postpartum and lactating women, or without conducting rigorous phase-specific safety screening, the field risks encountering severe, preventable adverse psychiatric outcomes that could jeopardize the regulatory approval and widespread acceptance of these therapies [2,11].

4.3. Comprehensive Analysis of Core Knowledge Gaps

To guide the next generation of psychedelic research, we have synthesized the core, unresolved knowledge gaps identified across the literature into clear thematic directions. Synthetic steroids found in oral contraceptives permanently suppress endogenous cycles, flattening 5-HT2A availability and altering hepatic CYP450 enzyme metabolism. This requires prospective, cohort-stratified Phase 1 trials comparing psilocybin pharmacokinetics/pharmacodynamics between women on oral contraceptives versus naturally cycling women.

Additionally, the absolute lack of human clinical data verifying if the follicular versus luteal phase significantly alters the subjective intensity or therapeutic longevity of a psilocybin session demands the integration of mandatory serum hormone panels (estradiol, progesterone, LH) and menstrual tracking diaries into all active clinical trials. Finally, the total absence of data on postmenopausal cohorts and the exact clearance kinetics of trace psilocin metabolites excreted via human breastmilk represent critical clinical vulnerabilities that must be addressed through targeted neuroimaging trials and controlled pharmacokinetic lactation studies.

4.4. Limitations of the Present Review

While this narrative review provides a comprehensive synthesis of the endocrine-psychedelic interface, several inherent methodological limitations must be acknowledged. First, due to the narrative nature of this work, it lacks the mathematical aggregation of data, pooling of effect sizes, and rigorous quantitative risk-of-bias assessments that characterize formal systematic reviews and meta-analyses. Second, a significant portion of the explicit mechanistic data regarding pregnancy and the postpartum period (specifically the highly critical Hatzipantelis 2025 study) relies on preclinical rodent models [33].

Rodents possess a highly distinct reproductive physiology, characterized by a short, 4-to-5-day estrous cycle rather than a 28-day menstrual cycle, and their pattern of gestational hormone withdrawal differs in timing and magnitude from human mothers [6,33]. Consequently, direct translation of these findings to human clinical populations must be performed with caution. Finally, because the contemporary psychedelic renaissance is still in its relative infancy, the available literature is heavily characterized by a lack of peer-reviewed human trials that feature explicit hormone stratification, forcing this review to rely on a synthesis of indirect neuroimaging data and preliminary qualitative surveys [2,15].

5. Conclusions

This narrative review underscores a critical truth for the advancement of modern psychiatry: personalized psychedelic medicine cannot exist without the integration of female neuroendocrinology. The molecular, neuroimaging, and preclinical evidence compiled herein suggests that female sex steroids—estradiol, progesterone, and testosterone—are not passive variables, but active, potent regulators of the central serotonergic system, potentially modulating the expression, sensitization, and clearance kinetics of the primary molecular targets of psilocybin [15,21,22]. The historical and contemporary practice of treating biological sex as a mere demographic covariate is an unsustainable methodological flaw that introduces major uncontrolled variance and unquantified safety risks into clinical trial data sets [2].

Moving forward, the scientific and medical community must mandate the integration of mandatory serum hormone tracking, menstrual cycle synchronization, and contraceptive stratification into the design of all future psychedelic clinical trials [2,13]. Furthermore, the alarming behavioral and neurodevelopmental findings from recent postpartum animal models serve as a critical reminder that specific reproductive transition windows possess unique neurobiological vulnerabilities that require dedicated, cautious exploration [33]. By dismantling the outdated "one-size-fits-all" dosing model and establishing an evidence-based, endocrinologically informed paradigm, psychedelic-assisted therapy can be safely, effectively, and precisely optimized to meet the unique physiological and psychological needs of women across their entire lifespan.

REFERENCES

1. Kessler, R. C., & Bromet, E. J. (2013). The epidemiology of depression across cultures. *Annual Review of Public Health, 34*, 119–136. https://doi.org/10.1146/annurev-publhealth-031912-114409
2. Cohen, Z. Z., & Blest-Hopley, G. (2025). Females in psychedelic research: A perspective for advancing research and practice. *ACS Pharmacology & Translational Science, 8*(8), 1837–1846. https://doi.org/10.1021/acsptsci.5c00255
3. GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. *The Lancet, 396*(10258), 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9
4. Albert, P. R. (2015). Why is depression more prevalent in women? *Journal of Psychiatry & Neuroscience, 40*(4), 219–221. https://doi.org/10.1503/jpn.150205
5. Lim, G. Y., Tam, W. W., Lu, Y., Ho, C. S., Zhang, M. W., & Ho, R. C. (2018). Prevalence of depression in the community from 30 countries between 1994 and 2014. *Scientific Reports, 8*, 2861. https://doi.org/10.1038/s41598-018-21243-x
6. Barth, C., Villringer, A., & Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Frontiers in Neuroscience, 9*, 37. https://doi.org/10.3389/fnins.2015.00037
7. Becker, J. B., McClellan, M. L., & Reed, B. G. (2017). Sex differences, gender and addiction. *Journal of Neuroscience Research, 95*(1–2), 136–147. https://doi.org/10.1002/jnr.23963
8. Anker, J. J., & Carroll, M. E. (2010). Sex differences in the effects of allopregnanolone on yohimbine-induced reinstatement of cocaine seeking in rats. *Psychopharmacology, 210*(1), 63–72. https://doi.org/10.1016/j.drugalcdep.2009.11.002
9. Calipari, E. S., Juarez, B., Morel, C., Walker, D. M., Cahill, M. E., Ribeiro, E., & Nestler, E. J. (2017). Dopaminergic dynamics underlying sex-specific cocaine reward. *Nature Communications, 8*, 13877. https://doi.org/10.1038/ncomms13877
10. Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2006). The pharmacology of psilocybin. *Addiction Biology, 7*(4), 357–364. https://doi.org/10.1080/1355621021000005937
11. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic substances. *Neuropsychopharmacology, 42*(1), 2105–2114. https://doi.org/10.1038/npp.2017.84
12. Carhart-Harris, R. L., Giribaldi, B., Erritzoe, D., Forsythe, G., Wall, M. B., Beliveau, V., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. *The Lancet Psychiatry, 3*(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7
13. Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. *JAMA Psychiatry, 78*(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
14. Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barriga, E. V., Wilson, L. I., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. *Cell Reports, 23*(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
15. Kugaya, A., Epperson, C. N., Zoghbi, S., van Dyck, C. H., Hou, Y., Fujita, M., & Innis, R. B. (2003). Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. *American Journal of Psychiatry, 160*(8), 1522–1524. https://doi.org/10.1176/appi.ajp.160.8.1522
16. Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews, 68*(2), 264–355. https://doi.org/10.1124/pr.115.011478
17. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences, 109*(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109
18. Shao, L. X., Liao, C., Dietz, I., Gooden, K. C., Khan, I., Greb, A. C., & Olson, D. E. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. *Neuron, 109*(16), 2535–2544. https://doi.org/10.1016/j.neuron.2021.06.008
19. Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. *Pharmacological Reviews, 71*(3), 316–344. https://doi.org/10.1124/pr.118.017160
20. Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. *Nature Reviews Neuroscience, 11*(9), 642–651. https://doi.org/10.1038/nrn2884
21. Kranz, G. S., Wadsak, W., Kaufmann, U., Savli, M., Baldinger, P., Gryglewski, G., & Lanzenberger, R. (2015). High-dose testosterone treatment increases serotonin transporter binding in transgender individuals: A longitudinal PET study. *Biological Psychiatry, 78*(8), 525–533. https://doi.org/10.1016/j.biopsych.2014.09.010
22. Fink, G., Sumner, B. E., Rosie, R., Grace, O., & Quinn, J. P. (1996). Estrogen control of central neurotransmission: Effect on mood, mental state, and memory. *Cellular and Molecular Neurobiology, 16*(3), 325–344. https://doi.org/10.1007/BF02088099

23. Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. *New England Journal of Medicine, 338*(4), 209–216. https://doi.org/10.1056/NEJM199801223380401
24. Taylor, C. M., Pritschet, L., Yu, S., & Jacobs, E. G. (2020). Progesterone shapes medial temporal lobe volume and functional connectivity across the human menstrual cycle. *NeuroImage, 220*, 117125. https://doi.org/10.1016/j.neuroimage.2020.117125
25. Sumner, B. E., & Fink, G. (1995). Estrogen increases the density of 5-HT2A receptors in cerebral cortex and nucleus accumbens in the female rat. *Journal of Steroid Biochemistry and Molecular Biology, 54*(1–2), 15–20. https://doi.org/10.1016/0960-0760(95)00075-B
26. Biegon, A., Reches, A., Snyder, L., & McEwen, B. S. (1983). Serotonin and estrogen interaction in the rat brain. *Life Sciences, 33*(8), 789–795. https://doi.org/10.1016/0024-3205(83)90053-X
27. Cyr, M., Landry, M., & Di Paolo, T. (2000). Modulation by estrogen-receptor agonists of 5-HT2A receptors in rat brain. *Neuropsychopharmacology, 22*(5), 513–520. https://doi.org/10.1016/S0893-133X(00)00085-3
28. Rybaczyk, L. A., Bashaw, M. J., Pathak, D. R., Moody, S. M., Gilders, R. M., & Holzschu, D. L. (2005). An overlooked connection: Serotonergic mediation of estrogen-related physiology and pathology. *BMC Women's Health, 5*, 12. https://doi.org/10.1186/1472-6874-5-12
29. Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., & Hathaway, H. J. (2008). Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. *Annual Review of Physiology, 70*, 165–190. https://doi.org/10.1146/annurev.physiol.70.113006.100518
30. Ettrup, A., da Cunha-Bang, S., McMahon, B., Lehel, S., Dyssegaard, A., Skibsted, A. W., Jørgensen, L. M., Hansen, M., Baandrup, A. O., Bache, S., Svarer, C., Kristensen, J. L., Gillings, N., Madsen, J., & Knudsen, G. M. (2014). Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. *Journal of Cerebral Blood Flow & Metabolism, 34*(7), 1188–1196. https://doi.org/10.1038/jcbfm.2014.68
31. Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). *Psychoneuroendocrinology, 28*(Suppl. 3), 1–23. https://doi.org/10.1016/S0306-4530(03)00098-2
32. Sacher, J., Neumann, J., Okon-Singer, H., Gotowiec, S., & Villringer, A. (2013). Sexual dimorphism in the human brain: Evidence from neuroimaging. *Magnetic Resonance Imaging, 31*(3), 366–375. https://doi.org/10.1016/j.mri.2012.06.007
33. Hatzipantelis, C. J., Liu, M., Love, A., Leventhal, S. J., Maera, H., Viswanathan, S., Avetisyan, E., Belinsky, L., Rangel, M. M., Jain, N. J., Kelly, M., Copeland, C., Khatib, Y. A., Fiehn, O., Olson, D. E., & Stolzenberg, D. S. (2025). Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. *Nature Communications, 16*(1), 8630. https://doi.org/10.1038/s41467-025-64371-5
34. Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. *Neuropharmacology, 61*(3), 364–381. https://doi.org/10.1016/j.neuropharm.2011.01.017
35. Dubey, N., Hoffman, J. F., Schuebel, K., Yuan, Q., Martinez, P. E., Nieman, L. K., Rubinow, D. R., Schmidt, P. J., & Goldman, D. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. *Molecular Psychiatry, 22*(8), 1172–1184. https://doi.org/10.1038/mp.2016.229
36. Hantsoo, L., & Epperson, C. N. (2020). Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. *Neurobiology of Stress, 12*, 100213. https://doi.org/10.1016/j.ynstr.2020.100213
37. Straumann, I., Holze, F., Becker, A. M., Ley, L., Halter, N., & Liechti, M. E. (2024). Safety pharmacology of acute psilocybin administration in healthy participants. *Neuroscience Applied, 3*, 104060. https://doi.org/10.1016/j.nsa.2024.104060